Chantale Bernatchez
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
The solid tumor microenvironment inhibits the functionality of tumor infiltrating T cells recognizing cognate tumor antigen, driving their differentiation towards terminal exhaustion. Interventions are sought to enhance the anti-tumor functionality of tumor-reactive T cells for clinical benefit. The functional genome regulating CD8 + T cell function against solid tumors was mapped by performing genome-wide, focused, and combination in vivo CRISPR/Cas9 screens using OT1 and PMEL TCR transgenic T cells in B16-OVA, MC38-gp100 and EG7-OVA syngeneic tumor models. The ability of the top single hits and combinations, which include Regnase-1 and SOCS1, to enhance CD8 + T cell anti-tumor function was evaluated in the OT1/B16-OVA model with large and established tumors, the disseminated PMEL/B16F10 tumor model, and in a novel murine TIL syngeneic model. The impact of Regnase-1 and SOCS1 single and dual-inactivation on the differentiation of exhausted CD8 + T cell subsets and on long-term persistent memory following tumor clearance was evaluated in OT1 CD8 + T cells in the B16-OVA model. The impact of single and dual-inactivation of Regnase-1 and SOCS1 on the anti-tumor function of experimental human T cell therapeutics was characterized in CRISPR/Cas9-engineered human TIL derived in vitro and in mesothelin-targeting CAR-Ts in vivo. NF-κB and cytokine signaling were identified as the top pathways regulating CD8 + T cell anti-tumor function, with Regnase-1 and Suppressor of Cytokine Signaling 1 (SOCS1) the top single and combination edits regulating the accumulation of tumor-specific TCR transgenic CD8 + T cells in syngeneic tumor models. Dual-inactivation of Regnase-1 and SOCS1 cooperated through non-redundant mechanisms to strongly expand intermediate (Tex int ) and effector (Tex eff ) exhausted CD8 + T cells within lymphoid tissues and tumor, with CD8 + T cells rewired to display an enhanced effector state and suppressed expression of TOX. Dual-edited persistent T effector memory cells (T em ) were formed following tumor clearance. Lastly, Regnase-1 and SOCS1 inactivation enhanced human Tumor Infiltrating Lymphocyte (TIL) and chimeric antigen receptor T cells (CAR-T) therapy functionality. Collectively, this study systematically mapped pathways regulating CD8 + T cell anti-tumor functionality, with Regnase-1 and SOCS1 dual-inactivation found to maximize anti-tumor function through non-redundant mechanisms.
Year:
2026
Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.
Year:
2025
Integrated gene set enrichment analysis of subgroups by body mass index BMI. This figure compares gene expression between overweight/obese (OW/OB) and normal (NL) BMI patients with metastatic melanoma across subgroups by sex, cohort, and tissue site. Supplementary Figure 2 presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients by subgroups. Red indicates upregulation in OW/OB verse NL.
Year:
2025
Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation in OW/OB verse NL. The far left column is all patients, and then, an analysis controlling for sex, cohort, and tissue site is shown in the 3 columns to the right.
Year:
2025
Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 x IQR. The red dots represent OW/OB patients and the blue dots represent NL patients by BMI. This is a subgroup analysis of Figure 5C.
Year:
2025
Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort. Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors from overweight/obese (OW/OB) patients by body mass index (BMI) verse normal (NL) BMI from The Cancer Genome Atlas (TCGA). Lines represent mean +/- SEM; each dot represents a single tumor.
Year:
2025
Immune cell analysis by BMI. A. Immunohistochemistry (IHC) analysis for CD8-, CD45RO-, FOXP3-, CD68-, GZMB-, PD-1-, LAG-3-, and CD3-positive cells in overweight/obese (OW/OB) verse normal (NL) tumors as defined by body mass index from the MD Anderson Cancer Center (MDA) cohort. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis for PD-L1-, CD45RO-, FOXP3-, EOMES-, GZMB-, PD-1-, TBET-, and TBET:FOXP3-positive cells in OW/OB verse NL tumors as defined by body mass index from the Gide cohort. Line represents median +/- interquartile range; each dot represents a single tumor.
Year:
2025
Supplementary Table 1: Baseline characteristics for patients included in the integrated gene set enrichment analysis (Figure 2-3) by cohort; Supplementary Table 6: The most frequent somatic alterations (alts) in patients with regionally metastatic melanoma by body mass index from The Cancer Genome Atlas cohort; Supplemental Table 7: Integrated gene set enrichment analysis for pathways associated with fatty acid metabolism by body mass index; Supplemental Table 8: Gene expression of selected genes of interest involved in fatty acid metabolism.
Year:
2025
Beta-diversity analysis stratified by sex based on Bray-Curtis dissimilarity represents microbiome samples with metastatic melanoma in terms of the two top principal components (explaining around 17% of variance) obtained from the principal coordinate analysis. Red dots are from overweight/obese (OW/OB) BMI patients, and blue dots are from normal (NL) BMI patients. Shading inside the dots indicates the female gender. This is a subgroup analysis of Figure 5B.
Year:
2025
Purpose: Overweight/obese (OW/OB) patients with metastatic melanoma unexpectedly have improved outcomes with immune checkpoint inhibitors (ICI) and BRAF-targeted therapies. The mechanism(s) underlying this association remain unclear, thus we assessed the integrated molecular, metabolic, and immune profile of tumors, as well as gut microbiome features, for associations with patient body mass index (BMI). Experimental Design: Associations between BMI [normal (NL n = 357) was batch corrected and gene set enrichment analysis (GSEA) by BMI category was performed. Metabolic profiling was conducted in a subset of patients ( x = 36) by LC/MS, and in flow-sorted melanoma tumor cells ( x = 37) and patient-derived melanoma cell lines ( x = 17) using the Seahorse XF assay. Gut microbiome features were examined in an independent cohort ( n = 371). Results: DNA mutations and copy number variations were not associated with BMI. GSEA demonstrated that tumors from OW/OB patients were metabolically quiescent, with downregulation of oxidative phosphorylation and multiple other metabolic pathways. Direct metabolite analysis and functional metabolic profiling confirmed decreased central carbon metabolism in OW/OB metastatic melanoma tumors and patient-derived cell lines. The overall structure, diversity, and taxonomy of the fecal microbiome did not differ by BMI. Conclusions: These findings suggest that the host metabolic phenotype influences melanoma metabolism and provide insight into the improved outcomes observed in OW/OB patients with metastatic melanoma treated with ICIs and targeted therapies. See related commentary by Smalley, p. 5
Year:
2025
Year:
2024
Year:
2024
Year:
2022
Collaborators (34)
Georgina V. Long
University of Sydney
Lauren Haydu
Assistant Professor of Biostatistics
Mayo Clinic
Carrie Daniel
Professor
The University of Texas MD Anderson Cancer Center
Michael A. Davies
-
Ralph J. DeBerardinis
University of Texas Southwestern Medical Center
Jennifer L. McQuade
The University of Texas MD Anderson Cancer Center
Jun Li
Associate Professor
University of North Carolina at Chapel Hill
Alexander M. Menzies
University of Sydney
Theodore S. Nowicki
University of California
Sean Bendall
Stanford University School of Medicine
Greg M. Delgoffe
-
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Vashisht Yennu Nanda
Associate Professor
The University of Texas MD Anderson Cancer Center
John Thompson
Clinical Professor
University of Sydney
Grant Fischer
Assistant Professor of Molecular Genetic Pathology (Tenure Track)
University of North Carolina at Chapel Hill
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Jiexin Zhang
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Elizabeth Burton
The University of Texas MD Anderson Cancer Center
Aditya Mishra
University of Georgia
Michael J. Overman
-
Glenn Hanna
Dana-Farber Cancer Institute
Christine Spencer
Parker Institute for Cancer Immunotherapy
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Dirk Schadendorf
University Hospital Essen
Han Liang
The University of Texas MD Anderson Cancer Center
James Wilmott
Associate Professor
The University of Sydney Library
yana najjar
University of Pittsburgh
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Nadim Ajami
Executive Director
The University of Texas MD Anderson Cancer Center
Richard A. Scolyer
Faculty Member
University of Sydney
Nagireddy Putluri
Professor (Tenured)
Baylor College of Medicine
Weiyi Peng
Director
University of Houston
Make your next move.
Prepare your application
Review drafts before you send them.